Augmented Versus Isolated Marrow Stimulation for Focal Chondral and Osteochondral Defects of the Knee: A Systematic Review of a Decade’s Comparative Evidence
Medical Sciences · 2026-11-06 · 14 (7) · 759
DOI: 10.3390/medsci14070759 ↗Abstract
Background/Objectives: Microfracture remains the most widely used first-line procedure for focal chondral defects of the knee, but its fibrocartilaginous repair deteriorates over time. This review asked whether adding an orthobiologic or scaffold to marrow stimulation changes clinical, structural or safety outcomes compared with isolated marrow stimulation, by augmentation type. Methods: PubMed, Scopus and the Cochrane Library (January 2016 to July 2026) and ClinicalTrials.gov were searched for randomized and non-randomized comparative studies with at least 12 months of follow-up (PROSPERO CRD420261484998, registered retrospectively). Risk of bias was assessed with RoB 2 and ROBINS-I; findings were synthesized without meta-analysis (SWiM) by effect direction, exploratory sign tests and unpooled standardized mean differences, and certainty was rated with GRADE. Results: Fifteen studies (six randomized; 630 patients; follow-up 12 months to 10 years) were included. Across augmentation types, the point estimate for function favored augmentation in eight out of nine independent evidence sources (p = 0.039) but not when the four unclassifiable studies were counted as unfavorable (8 of 13; p = 0.58), and clinically important IKDC differences occurred only in non-randomized cohorts. A structural advantage was statistically supported in two out of ten studies, in one only on a group-by-time interaction. Further surgery occurred mainly after isolated marrow stimulation, but events were few, and harms were inconsistently reported. Conclusions: Effects differ by augment and should not be generalized to augmentation as a class. Type I/III collagen membranes may improve patient-reported function, and cellular or autologous tissue products, chiefly adipose-derived, may improve pain and symptoms (low certainty); effects on structure, reoperation and safety are very uncertain. Adequately powered randomized trials of each augment are needed.
EUVIMED